Boutique CRO Redoxis is a small preclinical CRO specializing in inflammation and autoimmune conditions with in vivo, ex vivo, and in vitro capabilities, representing a targeted partner for early-stage efficacy and mechanism of action studies.

Full Service Lab With a fully equipped lab and immunology assay capabilities, Redoxis can handle end-to-end preclinical workflows from MoA to PK and in vivo efficacy, offering a one-stop solution for sponsors.

Strategic Partnership Recent involvement in a financed collaboration with Amarna Therapeutics on Alphavirus-based screening (AlphaSelect) underlines a readiness to co-develop platforms, presenting a lead opportunity for joint grant-funded or paid projects.

Eurostars Funding Participation in a €0.8 million grant indicates access to funded research avenues and potential for co-financed projects, which could be attractive to clients seeking cost-sharing preclinical programs.

Smaller Scale Team size of 11-50 and revenue under $1M positions Redoxis as an agile, customizable partner for mid- to late-seed biotech firms seeking flexible engagement models and personalized service.